Akatinol in the treatment of noncognitive neuropsychological disorders in neurogeriatric diseases

Abstract

The author gives the data available in the literature and her materials on the prevalence and degree of noncognitive neuropsychological disorders (NNPDs) in dyscirculatory encephalopathy (DE) with non-dementia cognitive impairments (CI) and in Alzheimer’s disease (AD) with mild to moderate stage dementia. Memantine (akatinol) therapy-induced changes in NNPDs are shown. It is emphasized that the significance of NNPDs in the general disease picture is now underestimated; in this connection their adequate therapy is not performed. This may result in a rapider progression of CI and a more significant reduction in daily activities in the patient. The high prevalence and multisymptompattern of NNPD are determined in both patients with DE and non-dementia CI and in those with AD and mild to moderate stage dementia. The degree of NNPDs correlates with the severity of cognitive defect and the low quality of life. Akatinol is noted to be clinically efficacious in DE and moderate CI against not only CI, but also NNPDs. In AD, symptomatic antidementia drugs (galantine, memantine, or their combination) arrest NNPDs in the first 3 months of therapy. Combined therapy should be recognized as best. The data available in the literature and the results of the authorХs studies show the need for further investigations of NNPDs in patients with CI in order to optimize the diagnosis and treatment of neurogeriatric diseases.

Keywords

• noncognitive neuropsychological disorders
• alzheimer’s disease
• dyscirculatory encephalopathy
• cognitive impairments